Picture of Pegbio Co logo

2565 Pegbio Co Share Price

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapMomentum Trap

Momentum

Relative Strength (%)
1m+137.12%
3mn/a
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-6.16%
50d MA+147.81%
200d MA+154.85%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value216.91
Price to Tang. Book216.91
Price to Free Cashflown/a
Price to Salesn/a
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-462.76%
Return on Equity-233.95%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Pegbio Co EPS forecast chart

Profile Summary

PegBio Co Ltd is a China-based company primarily engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    January 1st, 1970
    Incorporated
    May 13th, 2008
    Public Since
    May 27th, 2025
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    hk flag iconStock Exchange of Hong Kong Limited
    Shares in Issue
    385,955,532

    2565 Share Price Performance

    Upcoming Events for 2565

    Similar to 2565

    Picture of 3D Medicines logo

    3D Medicines

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of 3SBio logo

    3SBio

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ab&B Bio Tech Co JS logo

    Ab&B Bio Tech Co JS

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of AIM Vaccine Co logo

    AIM Vaccine Co

    hk flag iconStock Exchange of Hong Kong Limited

    Picture of Ascletis Pharma logo

    Ascletis Pharma

    hk flag iconStock Exchange of Hong Kong Limited

    FAQ